In light of the critical drug shortages facing the U.S., The Association for Clinical Oncology (ASCO) has issued guidance for the treatment of gastrointestinal malignancies in the context of limited drug availability.
The guidance provides five general principles outlining reasonable drug substitutes and how to prioritize patient needs. The guidance focuses on:
- Upper gastrointestinal malignancies
- Pancreato-biliary malignancies
- Small intestine malignancies
- Colorectal cancer
- Anal cancer
Read the full guidance for further details.